New obesity drug SA030 enters first human safety trial
Disease control
Not yet recruiting
This early-stage study tests a single dose of SA030 injection in 40 overweight or obese adults aged 18–55. The main goal is to check safety and how the body handles the drug. It is the first time SA030 is given to humans, so results will guide future research.
Phase: PHASE1 • Sponsor: Suzhou Siran Biotechnology Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC